OPTIMA Study New Clinical Trial

Posted by Jo Ann K @jkiemen, Sep 20, 2018

Has anyone looked into this clinical trial called OPTIMA http://www.marketwired.com/press-release/savara-initiates-phase-2a-clinical-study-molgradex-treatment-ntm-lung-infection-nasdaq-svra-2246289.htm Let me know if any one has researched any information on this new treatment!!!!!!!!!!!!!!!!!!

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

to the group. This is my reply from the pharma company:
Dear Mrs. Kiemen,

Many thanks for your enquiry and interest in our NTM investigational drug. As I am sure you are aware, Molgradex is not an antibiotic but an immunostimulant (GM-CSF) – the goal of treatment being to help your innate immune system better clear this difficult to treat intracellular infection (with our without antibiotics). There have been some promising results with this treatment concept in the literature (see here). Our current OPTIMA/NTM study is being conducted outside of the US and is nearing completion of enrollment. The topline study results will be available in Q2 of 2019 (with interim results Q4 2018) – assuming success in this study, we will likely launch a new study that will include US centers.

In addition to the above, we will be launching a new OPTIMA/CF study in the US early next year – this study will only enroll Cystic Fibrosis patients infected with NTM.

If you have any additional questions, please let me know. If you wish to receive alerts from Savara, please signup here.

Best regards,
Rob

Rob Neville
CEO

Email: rob.neville@savarapharma.com
www: savarapharma.com

Savara Pharmaceuticals
6836 Bee Cave Road, Building 3, Suite 200
Austin, TX 78746, USA

CONFIDENTIALITY NOTICE:
This e-mail, including attachments, is intended for the person(s) or company named and may contain confidential and/or legally privileged information. Unauthorized disclosure, copying or use of this information may be unlawful and is prohibited. If you are not the intended recipient, please delete this message and notify the sender.

REPLY

@jkiemen ..Thanks for contacting Savara and posting their response. How promising! Kate

REPLY

@jkiemen
Thanks for looking into this study!
Looking into ways of using ones immune response to deal with this infection is definitely a move in the right direction. Many cancer therapies are finally moving more and more into this direction also of immune targeted therapies.

Please keep us updated as you hear more!
Shari

REPLY
@jkiemen

to the group. This is my reply from the pharma company:
Dear Mrs. Kiemen,

Many thanks for your enquiry and interest in our NTM investigational drug. As I am sure you are aware, Molgradex is not an antibiotic but an immunostimulant (GM-CSF) – the goal of treatment being to help your innate immune system better clear this difficult to treat intracellular infection (with our without antibiotics). There have been some promising results with this treatment concept in the literature (see here). Our current OPTIMA/NTM study is being conducted outside of the US and is nearing completion of enrollment. The topline study results will be available in Q2 of 2019 (with interim results Q4 2018) – assuming success in this study, we will likely launch a new study that will include US centers.

In addition to the above, we will be launching a new OPTIMA/CF study in the US early next year – this study will only enroll Cystic Fibrosis patients infected with NTM.

If you have any additional questions, please let me know. If you wish to receive alerts from Savara, please signup here.

Best regards,
Rob

Rob Neville
CEO

Email: rob.neville@savarapharma.com
www: savarapharma.com

Savara Pharmaceuticals
6836 Bee Cave Road, Building 3, Suite 200
Austin, TX 78746, USA

CONFIDENTIALITY NOTICE:
This e-mail, including attachments, is intended for the person(s) or company named and may contain confidential and/or legally privileged information. Unauthorized disclosure, copying or use of this information may be unlawful and is prohibited. If you are not the intended recipient, please delete this message and notify the sender.

Jump to this post

@jkiemen Thanks for writing to them and great they replied so fast! Drug sounds just what we need.

REPLY
Please sign in or register to post a reply.